Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (221-230 of 236) with videos related to

Pageof 24
Sort By:
JAMA|June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trialRichard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.
Journal of Translational Medicine|December 2, 2015
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014Paolo A Ascierto, Michael Atkins, Carlo Bifulco, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
Blood Advances|February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemiaAthalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Journal of Translational Medicine|November 17, 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, et al.
Research Square|November 30, 2021
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunctionSherin J Rouhani, Jonathan A Trujillo, Athalia R Pyzer, et al.
Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.
Journal for Immunotherapy of Cancer|April 18, 2020
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, et al.
Pageof 24

Showing results (221-230 of 236) with videos related to

Sort By:
Pageof 24
JAMA|June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trialRichard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.
Journal of Translational Medicine|December 2, 2015
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014Paolo A Ascierto, Michael Atkins, Carlo Bifulco, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
Blood Advances|February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemiaAthalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Journal of Translational Medicine|November 17, 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015Paolo A Ascierto, Sanjiv Agarwala, Gerardo Botti, et al.
Research Square|November 30, 2021
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunctionSherin J Rouhani, Jonathan A Trujillo, Athalia R Pyzer, et al.
Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.
Journal for Immunotherapy of Cancer|April 18, 2020
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, et al.
Pageof 24